Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Rating of "Moderate Buy" from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company.

BAYRY has been the topic of several recent analyst reports. DZ Bank raised Bayer Aktiengesellschaft from a "strong sell" rating to a "hold" rating in a report on Thursday, April 9th. UBS Group raised Bayer Aktiengesellschaft from a "neutral" rating to a "buy" rating in a research report on Monday, March 16th. Zacks Research lowered Bayer Aktiengesellschaft from a "hold" rating to a "strong sell" rating in a research report on Tuesday, March 24th. Finally, Barclays upgraded Bayer Aktiengesellschaft from an "equal weight" rating to an "overweight" rating in a research note on Tuesday, January 6th.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY opened at $11.11 on Friday. Bayer Aktiengesellschaft has a 1 year low of $6.20 and a 1 year high of $14.85. The stock has a market capitalization of $43.66 billion, a PE ratio of -10.01 and a beta of 0.62. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.63 and a current ratio of 1.01. The stock has a 50-day simple moving average of $11.46 and a 200-day simple moving average of $10.76.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, hitting analysts' consensus estimates of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. The firm had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.2 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.